Optellum and Volpara Health have announced a strategic agreement aimed at integrating AI-driven imaging solutions for lung and breast cancer detection. The collaboration will provide Volpara’s network of over 3,500 U.S. healthcare facilities with access to Optellum’s Virtual Nodule Clinic, an AI-powered tool designed to assess the likelihood that a lung nodule is cancerous.

Volpara, a subsidiary of Lunit, develops software for early cancer detection, with a focus on breast imaging and risk assessment. Its technology helps quantify breast tissue density, optimize mammography workflows, and refine patient risk assessments. By combining these capabilities with Optellum’s lung cancer prediction tools, the companies aim to offer clinicians a more comprehensive approach to evaluating cancer risk.

“Every patient deserves the earliest possible diagnosis, and by coming together with Volpara, more clinicians will have a more complete picture of their patients' health,” said Johnathan Watkins, CEO of Optellum.

The partnership comes as AI continues to play a growing role in cancer screening and early detection. Optellum’s platform has received FDA 510(k) clearance and Medicare reimbursement, supporting its adoption in clinical settings.

“Getting more evidence-based, early detection technologies into the hands of clinicians will allow for more accurate detection and ultimately save more families from cancer,” said Teri Thomas, CEO of Volpara Health.

Optellum is based in Oxford, United Kingdom, with U.S. operations in Houston, Texas. Volpara is headquartered in Wellington, New Zealand, with an office in Seattle.